



PRESS RELEASE

September 27, 2022

Ziccum reopens application for CEPI funding on thermostable vaccines with new partner

Ziccum AB (publ) ('Ziccum') today announces that it has reopened its application process for CEPI's Call for Proposals (CfP) from companies developing innovative technologies to improve vaccine thermostability. Ziccum will submit an Expression of Interest (EoI) with a new partner – a well-established, innovative biotechnology company.

Ziccum will now be submitting a formal EoI, together with a new partner, to CEPI's Call for Proposals for companies developing innovative technologies to improve vaccine thermostability. The partner is a well-established biotech company with novel technology and extensive experience within mRNA vaccine formulation and development.

Ziccum previously communicated (July 21, 2022) that it had decided not to apply for the CEPI funding, not having a relevant partner for the international implementation of manufacturing. Subsequent to that decision, Ziccum has been approached by this biotechnology partner to develop a joint application to improve vaccine thermostability. The CEPI CfP targets manufacturing organizations that can implement thermostable vaccine facilities globally.

Ziccum CEO Ann Gidner: "This is a very good union with a shared commitment to innovation in mRNA vaccines. The expertise and capabilities on our partner's side are solid, inspiring and exciting. We look forward to completing our application."

About CEPI: CEPI, the Coalition for Epidemic Preparedness Innovations, funds a wide range of research projects to develop vaccines through donations from public, private, charitable and civil society organizations. CEPI is headquartered in Oslo, Norway.

For more information about Ziccum, please contact:

Ann Gidner,
CEO Ziccum
Mail: gidner@ziccum.com
Mobile: +46 722140141

Fredrik Sjövall,
Chairman of the Board, Ziccum AB
Mail: sjovall@ziccum.com
Mobile: +46 706 45 08 75

Ziccum's Certified Adviser is Erik Penser Bank AB

About Ziccum

Ziccum is developing new thermostable versions of vaccines and biologic materials for licensing to vaccine providers, developers, manufactures and CDMOs in the global pharmaceutical industry. Ziccum's patented drying technology, LaminarPace, is unique. It can dry-formulate temperature-sensitive vaccine materials at room temperature with high yields and low waste. These robust, thermostable dry powders could be stored and transported worldwide with no need for cold chain refrigeration or freezing. Ziccum is listed on the Nasdaq First North Growth Market

Attachments

[Ziccum reopens application for CEPI funding on thermostable vaccines with new partner](#)